Slide 1: Harnessing the Power of the Immune System
Harnessing the Power of the Immune System Nasdaq: IMNN © 2023 IMUNON, Inc. PAGE 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and any statements made during any presentation or meeting contain forward-looking statements related to Imunon, Inc. (“Imunon”) under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks an
Slide 3: Experienced Management Team
Experienced Management Team Corinne Le Goff, PharmD MBA Khursheed Anwer, PhD MBA Jeffrey W. Church Anthony Recupero, PhD President, CEO and Director Executive Vice President and Executive Vice President, CFO & Vice President Chief Science Officer Corporate Secretary Business Development © 2023 IMUNO
Slide 4: Developing new medicines that harness the body's immune system
• Leveraging innovative non-viral DNA platform with proprietary synthetic delivery systems and multiple potential indications Developing new • Initial clinical focus is on immuno-oncology and infectious medicines that diseases harness the • Already tested in humans with a trial underway in ovarian b
Slide 5: Our Disruptive Non-Viral DNA Technology Toolkit in Infectious Diseases and Immuno-Oncology
Our Disruptive Non-Viral DNA Technology Toolkit in Infectious Diseases and Immuno-Oncology Proprietary Synthetic Delivery and Facilitating System, that promotes DNA Protection, Uptake, Bioavailability and Enhanced Antigen Expression NEXT GEN NEXT GEN IMMUNO Gene Therapy MODULATION PROPHYLACTIC Proph
Slide 6: IMUNON's Pipeline of DNA-based Transformative Medicines
IMUNON’s Pipeline of DNA-based Transformative Medicines Modality Program Indication(s) Discovery IND Phase 1 Phase 2 Partnerships enabling Advanced Ovarian, IL-12 (OVATION) Fallopian Tube or Primary IMNN-001 (formerly GEN-1) Intraperitoneal (IP) Peritoneal Cancer TheraPlas IL-12 IP in Advanced Ovari
Slide 7: IMUNON's Non-viral DNA Vaccine Platform is addressing these challenges
IMUNON’s Non-viral DNA Vaccine Platform is addressing these challenges Durability of Flexible Speed protection manufacturing Durable antigen expression Simple handling and Non-viral DNA is a platform induces robust distribution ability to go from sequence immunological response stability and long sh
Slide 8: Demonstrated Immunogenicity of our Vaccine pre-clinically
Demonstrated Immunogenicity of our Vaccine pre-clinically Over 90% Protection From Live Viral Challenge Viral Clearance by PlaCCine is Comparable to mRNA Vaccine Clearance is Sustainable with Efficiency >99% by PCR assay PlaCCine Induces Robust Immune Response after a Single Injection Wistar Institu
Slide 9: PlaCCine Vaccines Provide Durable Cellular Response
PlaCCine Vaccines Provide Durable Cellular Response >12-months Durability in Mice in a two-dose vaccination design 22-002 (No boost) 22-002 (No boost) 800 800 T-cell Response (IFN-g) 600 600 SFC/106 cells SFC/106 cells 400 400 200 200 0 0 PBS PBS PBS pVac15 pVac-15 pVac15 pVac16 pVac-16 pVac16 pVac1
Slide 10: PlaCCine is Stable at 4°C for at Least 9 Months
PlaCCine is Stable at 4⁰C for at Least 9 Months Immunogenicity Studies in Mice Simplified Supply Chain Around the world 4⁰C Storage 1 3 6 9 12 Months © 2023 IMUNON, Inc. PAGE 10
Slide 11: IMNN-101: Plug & Play Design Allows for a Rapid Response to Changing Pathogen
IMNN-101: “Plug & Play” Design Allows for a Rapid Response to Changing Pathogen Seasonal COVID-19 Booster, adapted for the latest strain • January 2023 FDA VRBPAC (Vaccines and Related Biological Products Advisory Committee) agreed that an annual COVID shot is C AA optimal. TTG • The FDA is proposin
Slide 12: IMNN-001 Targets the Micro-Environment of Ovarian Cancer
IMNN-001 Targets the Micro-Environment of Ovarian Cancer Local production of safe and durable levels of a powerful anti-cancer immune agent, IL-12 IMNN-001 Intracavity infusion of IMNN-001 has demonstrated durable and local expression of IL-12 in the peritoneum No supraphysiological increases in IL-
Slide 13: Interim OVATION 2 Data Indicates Subjects on IMNN-001 who are BRCA-/HRP may have Improved PFS
Interim OVATION 2 Data Indicates Subjects on IMNN-001 who are BRCA-/HRP may have Improved PFS Sub-population of patients with the greatest medical need Targeted Therapy Approach HRP (homologous recombination proficient with no BRCA 1/2 mutations) • Early data suggests 3-month improvement in this ide
Slide 14: Synergistic Antiangiogenic Effect of IMNN-001 + bevacizumab in Ovarian Cancer
Synergistic Antiangiogenic Effect of IMNN-001 + bevacizumab in Ovarian Cancer SKOV-3 Ovarian Cancer in Nude Mice Key Rationale for Combination of IMNN-001 with Avastin® 90 Control 80 mIMNN-001 • Synergistic efficacy potential 70 Avastin (low/med/high) mIMNN-001 + Avastin (low/med/high) of VEGF level
Slide 15: Financial Summary & Upcoming Key Milestones
Financial Summary & Upcoming Key Milestones: Robust Flow of Value Creating Activities Cash , Cash Equivalents & Investments IMNN-001 OVATION 2 IMNN-001 OVATION 2 Interim Data Topline Results $ $37.3M As of March 31, 2023 Interim Results IMNN-001 + bevacizumab Shares Outstanding IMNN-101 IMNN-101 SAR